细胞培养蛋白 | Recombinant Human EGF
表皮生长因子(EGF)是由53个氨基酸组成的多肽,以1217个氨基酸残基的前体形式合成蛋白，经水解后发挥生物学活性,存在于唾液腺和人尿液提取物中[1]。EGF可诱导小鼠牙齿和眼睑的提前发育、抑制胃酸分泌、促进表皮的生长及角化过程。人EGF(hEGF)与小鼠EGF(mEGF)的多肽序列虽然在16个位点处不同，但两者的生物学活性基本相同，并能结合于同一膜受体。EGF及其受体信号也与肿瘤的发生和预后密切相关，EGF 受体抑制剂可用于小细胞肺癌、胃癌等恶性肿瘤疾病的治疗[1-3]。
EGF通过与细胞膜上受体结合后激活多种酶发挥生物学作用，对炎性细胞、成纤维细胞表皮细胞及血管内皮细胞具有趋化作用，能够促进DNA、RNA 和羟脯氨酸的合成，调节蛋白质合成，完善胶原蛋白的构建，加快创面愈合速度[4]。研究发现EGF是一种强力的细胞分裂促进因子，有广泛的促进上皮细胞分裂增殖的作用，其以自分泌和旁分泌的方式作用于创面，促进表皮细胞及成纤维细胞等修复细胞的分裂、增殖，促进创面再上皮化，对血管生成也具有一定的诱导作用[5]。同时EGF还能刺激上皮细胞合成分泌胶原、透明质酸等细胞外基质，促进结缔组织细胞的生长，促进新生肉芽组织形成和伤口的再上皮化，加速皮肤、角膜及胃肠道等多种组织的创伤愈合，与肝的再生和创伤修复关系密切[6]。
Expression Host : CHO
Purity : ≥95%, by SDS-PAGE
Endotoxin : ≤10 EU/mg by the LAL method
Bioactivity
Recombinant Human EGF (Cat. No. Y00801) stimulates proliferation of NIH3T3 cells. The ED50 for this effect ≤0.3 ng/mL. The acivity of Y00801 was equivalent to other competing products.
参考文献
[1] Pirker R. What is the best strategy for targeting EGF receptors in non-small-celllung cancer? [J]. Future Oncol 2015; 11(1): 153-67.
[2] Moschini l,Dell'Anna C,Losardo PL,Bordi P, D'Abbiero N, Tiseo M.Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutationsand EGF receptor tyrosine kinase inhibitors[J]. Future Oncol 2015; 11(16): 2329-42.
[3] C.S. Swindle, K.T. Tran, T.D. Johnson, P. Banerjee, A.M. Mayes, L. Griffith, A.Wells, Epidermal growth factor (EGF)-like repeats of human tenascin-C asligands for FGF receptor[J]. The Journal of cell biology 154 (2001)459-468.
[4] Yu FS, Yin J, Xu K, Huang J. Growth factors and corneal epithelial woundhealing[J].Brain Res Bull 2010;81(2-3):229-35.
[5] Ya NH, Wen YQ, Qing P, Yu-FY, Kim YX, Marjorie F. Lou.Reactive oxygen species (ROS) are essential mediators in epidermal growth factor (EGF)-stimulated corneal epithelial cell proliferation, adhesion, migration, and woundhealing[J].Experimental Eye Research,2009(6).
[6] Bettina Klenkler, Heather Sheardown.Growth factors in the anterior segment: role in tissue malntenance, wound healing and ocular pathology[J].Experimental Eye Research,2004(5).
